


PCT / CA 00/00483
31 MAY 2000 (31.05.00)

4

PA 242710



REC'D 03 JUL 2000
WIPO PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME;

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

CA 00/00483

May 05, 2000

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/131,469

FILING DATE: April 28, 1999

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

P. R. Grant

P. R. GRANT
Certifying Officer

PROVISIONAL APPLICATION COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53 (b)(2).

Docket Number		10662-88"USPR"FC/ld		Type a plus sign (+) inside this box→	+
INVENTOR(s)/APPLICANT(s)					
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)		
SMITH BORDIGNON	Lawrence Vilceu	C.	2950 Lafontaine, Saint-Hyacinthe, Quebec, Canada, J2S 2H9 2790 Sicotte, Saint-Hyacinthe, Quebec, Canada J2S 2L5		
TITLE OF THE INVENTION (280 characters max)					
TELOPHASE ENUCLEATED OOCYTES FOR NUCLEAR TRANSFER					
CORRESPONDENCE ADDRESS					
Mrs. France Côté SWABEY OGILVY RENAULT 1981 McGill College Avenue, Suite 1600 Montréal					
STATE	Québec	ZIP CODE	H3A 2Y3	COUNTRY	Canada
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/>	Specification	Number of Pages	19	<input type="checkbox"/>	Small Entity Statement
<input checked="" type="checkbox"/>	Drawings	Number of Sheets	1	<input type="checkbox"/>	Other (specify)
METHOD OF PAYMENT (check one)					
<input checked="" type="checkbox"/>	A check or money order is enclosed to cover the Provisional filing fees			PROVISIONAL	
<input type="checkbox"/>	The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number			FILING FEE AMOUNT (\$)	\$150.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No

☐ Yes, the name of the U.S. Government agency and the Government contract number are: _____

Respectfully submitted,

SIGNATURE

France Côté

Date

04/27/1999

TYPED or PRINTED NAME

France Côté

REGISTRATION NO.
(if appropriate)

37,037

☐ Additional inventors are being named on separately numbered sheets attached hereto

PROVISIONAL APPLICATION FILING ONLY

Burden Hour Statement This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Office of Assistance Quality and Enhancement Division, Patent and Trademark Office, Washington, DC 20231, and to the Office of Information and Regulatory Affairs, Office of Management and Budget (Project 0651-0037), Washington, DC 20503. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

TELOPHASE ENUCLEATED OOCYTES FOR NUCLEAR TRANSFER

BACKGROUND OF THE INVENTION

(a) Field of the Invention

The present invention relates to an improved
5 method for obtaining an enucleated host oocyte for
transferring nuclei from embryonic, germinal and
somatic cells with the objective of cloning or
multiplying mammals, and to a method of reconstituting
an animal embryo.

10 (b) Description of Prior Art

The technique of nuclear transfer has been
widely used to multiply embryos by transferring
blastomere nuclei from early-stage embryos into
enucleated oocytes. This technique enables an increase
15 in the yield of embryos produced from parents of top
genetic value, enabling to accelerate the annual
genetic gain within an animal population (Nicholas,
Smith, 1983). Nuclear transfer has also been used with
nuclei from cell lines derived from embryonic (Campbell
20 et al. 1996), fetal and adult tissue (Wilmut et al.
1997). By using nuclei from an unlimited source,
nuclear transfer from cell lines enables not only the
production of a larger number of genetically identical
offspring but also an opportunity for modifying the
25 genetic characteristic of cells *in vitro* prior to the
production of live offspring, enabling the production
of transgenic mammals (Cibelli et al. 1998a; Schnieke
et al. 1997). Moreover, the use of cells from adult
animals for nuclear transfer, either directly (Wakayama
30 et al. 1998) or through previous *in vitro* passage
(Wells et al. 1999), enable the multiplication
(cloning) of animals of known phenotypes.

Basically, the nuclear transfer technique
requires a donor nucleus to provide the genetic
35 material of choice and a host oocyte to provide the

663240-6-9122-09

cytoplasm that plays a role in reprogramming the nucleus to support embryo development. With the nuclear and cytoplasm sources in hand, three main steps are required to reconstruct an oocyte by nuclear transfer.

5 First, host oocytes need to be enucleated to remove all nuclear genetic material. This step is usually performed by microsurgical removal of the chromosomes from either a metaphase plate or pronuclei. Second, donor nuclei need to be introduced into the oocyte
10 (nuclear transfer). This step is normally obtained by fusing the membranes of the nuclear donor cell and the host oocyte. However, nuclear transfer can also be obtained by traversing the oocytes plasma membrane and microinjecting the nucleus directly into the host
15 cytoplasm. Finally, non-activated host oocytes need awakening from their meiotic arrest (oocyte activation). This step can be achieved by exposing the oocyte to a physical stimulus, such as temperature changes or an electric shock, or exposing the oocyte to
20 chemical agents, such as ethanol or exogenous calcium. The order in performing each of the steps above can vary in different situations and may have an important effect on the ability of the reconstructed oocyte to undergo further development.

25 In mice, oocyte enucleation was performed after fertilization by visualizing and removing the pronuclei by microsurgery. This enucleation technique is less efficient in other mammals due to the higher density of cytoplasm resulting in poor visualization of pronuclei.
30 Moreover, attempts to use pronuclear-stage enucleated oocytes led invariably to poor developmental rates when using cleavage stage blastomeres as nuclear donors. Improved development after nuclear transfer was achieved initially in sheep (Willadsen, 1986) and later
35 in other mammals using host oocytes that had not been

50134459-042899

activated at the time of fusion. However, a problem remained that metaphase stage chromatin cannot be visualized easily by microscopy in most mammals. Willadsen (1986) proposed an enucleation procedure in which sheep oocytes were blindly divided into halves either containing or not the first polarbody. To avoid a large loss of cytoplasm during enucleation, this procedure was later improved by using a DNA vital stain (Bisbenzimidazole; Hoechst) and ultraviolet (UV) irradiation to check whether the MII plate after removal of small portions of cytoplasm (reviewed by (Smith, 1992). The most common procedure of oocyte enucleation is to expose secondary oocytes to bisbenzimidazole, blindly remove a cytoplasmic fragment surrounding the first polarbody and then expose the oocyte to UV to ascertain whether enucleation was correctly performed. On average this procedure correctly enucleates between 60 to 80 percent of oocytes. Another possible limitation of this procedure is that oocytes are exposed both to UV irradiation and Hoechst 33342 that have been shown to have detrimental effects on the cytoplasm (Smith, 1993).

As mentioned above, host oocytes are able to support better development after nuclear transfer when compared to pronuclear-enucleated host zygotes. A further advancement of the nuclear transfer technique was obtained when it was shown that MII-stage enucleated oocytes either aged or activated before fusion support better development (Stice et al. 1994). The problem of using young non-activated oocytes is caused by incompatibilities between the cell cycle stages of the nuclear donor cell and the host cytoplasm. Metaphase arrested secondary (MII) oocytes have high levels of a Maturation Promoting Factor (MPF), a cellular activity that is responsible for

maintaining the chromatin condensed without a nuclear envelop. When blastomere interphase-stage nuclei containing decondensed chromatin are introduced into an MII oocyte, MPF leads to a rapid breakdown of the nuclear membrane and premature chromosome condensation (PCC) (Collas et al. 1992). However, PCC is believed to be detrimental only when induced during the DNA synthesis stage (S-phase) of cell cycle. This is particularly problematic when using donor nuclei from blastomeres since these undergo S-phase for most time in between cell divisions. On the other hand, enucleated oocytes that have been activated or aged before fusion to nuclear donor cells have lower levels of MPF and, therefore, do not cause PCC.

With the exception of blastomeres, most other cell types have longer gaps both before (G1-phase) and after (G2-phase) the S-phase and, therefore, are less susceptible to the harmful effects of S-phase PCC when fused to a MII oocytes. Because high MPF levels cause the breakdown of the nuclear membrane, MII stage host oocytes are believed to facilitate interactions between donor nuclei and putative oocyte cytoplasmic 'factors' required for reprogramming the chromatin of nuclei derived from cells further advanced in differentiation. Several examples in the literature report on the advantages of passaging further differentiated donor nuclei in non-activated MII oocytes before activating the reconstructed oocyte. In cattle, nuclei from an embryonic cell line supported significantly higher yield of blastocyst development and more 30 d pregnancies when fused to enucleated oocytes 4 h before activation (Stice et al. 1996). In mice, significantly more embryos reconstructed with cumulus cell nuclei developed to the blastocyst stage by exposing the donor nucleus to MII cytoplasm for between 1 and 6 h before

It would be highly desirable to be provided
20 with an improved method of reconstituting an animal
embryo.

The present invention described below is
25 contrary to current knowledge in that we are teaching
use of an activated oocyte as recipient for nuclei
derived from cells from embryonic and somatic cell
lines.

One aim of the present invention is to provide
30 an improved method for obtaining an enucleated host
oocyte for transferring nuclei from embryonic, germinal
and somatic cells with the objective of cloning or
multiplying mammals.

Another aim of the present invention is to provide an improved method of reconstituting an animal embryo.

5 In accordance with the present invention there is provided a method of preparing an enucleated host oocyte for transferring nuclei from embryonic, germinal or somatic cells, which comprises the steps of:

- a) activating oocyte by artificial means; and
- 10 b) enucleating said activated oocyte when said activated oocyte is undergoing the expulsion of a second polarbody or when said activated oocyte has recently expelled second polarbody (Tel-II).

15 The oocyte of step a) has a first polarbody and said artificial means is chemical means, such as ethanol or ionomycin.

Step b) may be performed after oocytes are cultured for a period of time sufficient to allow for extrusion of a second polarbody.

20 ~~Step b) may be performed with oocytes in a medium with cytoskeletal inhibitors.~~

Step b) may be effected by microsurgically removing said second polar with about one tenth of the cytoplasm surrounding said second polarbody.

25 The preferred oocyte is a secondary (M-II) oocyte.

In accordance with the present invention, there is provided a method of reconstituting an animal embryo, which comprises the steps of:

- 30 a) activating oocyte by artificial means;
- b) enucleating said activated oocyte when said activated oocyte is undergoing the expulsion of a second polarbody or when said activated oocyte has recently expelled second polarbody
- 35 (Tel-II);

- c) transferring a diploid nucleus in said enucleated oocyte to obtain a reconstructed oocyte with a diploid chromosomal content; and
- d) culturing *in vitro* said reconstructed oocyte and/or transferring said reconstructed oocyte into a reproductive tract of a suitable surrogate mother to enable development into an animal embryo.

10 **BRIEF DESCRIPTION OF THE DRAWING**

Fig. 1 illustrates a schematic protocol of the technique of telophase enucleation for nuclear transfer.

15 **DETAILED DESCRIPTION OF THE INVENTION**

The present invention relates to a method of producing embryos by nuclear transplantation from embryonic, germinal and somatic cells lines. Nuclear transfer procedures have invariably initiated with the enucleation of host oocyte. The enucleation procedure is followed by one of the following: (a) activation followed by fusion; (b) concurrent activation and fusion; or (c) fusion followed by activation. Whereas the procedure in which oocytes are (a) enucleated, activated and then fused is used mostly for embryonic blastomeres, most techniques applied for further differentiated donor nuclei use the procedure where oocytes are enucleated, (b) fused and activated concurrently or (c) fused and later activated. Although the different steps in the nuclear transfer procedure have been described previously (U.S. Patent No. 4,999,384; U.S. Patent No. 5,057,420; U.S. Patent No. 5,843,754 and patent applications Nos. PCT/GB96/02098, PCT/US98/00002, PCT/US98/12800, PCT/US98/12806, and PCT/US97/12919), this invention

describes a sequence of steps in the nuclear transfer procedure that is novel (Fig. 1).

As illustrated in Fig 1, Step 1 involves the activation of secondary (M-II) oocytes by artificial means. Step 2 is performed shortly after activation when the oocyte is undergoing the expulsion or recently expelled the second polarbody (Tel-II). Step 3 relates to the transfer of a nucleus from any source with the purpose of reconstructing the oocyte with a diploid chromosomal content.

Step 1 (oocyte activation)

Oocytes are obtained either *in vivo* or *in vitro* and cultured in maturation medium. After maturation, oocytes are denuded of cumulus cells and those with a first polarbody are parthenogenetically activated by chemical means using ethanol or ionomycin. After activation, oocytes are cultured for a few hours to allow for extrusion of the second polarbody.

Step 2 (oocyte enucleation)

After activation, oocytes can be placed in medium with cytoskeletal inhibitors to facilitate microsurgery. Only oocytes with a second polarbody extruded or partially extruded are used. Approximately one tenth of the cytoplasm surrounding the second polar body is microsurgically removed with the second polarbody.

Step 3 (nuclear transfer)

After enucleation, a single cell containing a diploid nucleus is introduced into the enucleated oocyte either by cell fusion or microinjection (nuclear transfer). The reconstructed oocyte is then cultured *in vitro* and/or transferred into the reproductive tract of a suitable surrogate mother to enable further development.

The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.

5

EXAMPLE 1

Telophase Enucleation

Follicles with 2 to 8 mm diameter were aspirated from bovine slaughterhouse ovaries. Oocytes with a homogeneous cytoplasm and several layers of cumulus cells were selected and placed in maturation within 1 h from follicular aspiration. At 28 h after maturation oocytes were denuded of cumulus cells and those with a first polarbody were used in the experiment. Oocytes were exposed to 7% ethanol for 5 min, washed and placed in maturation medium for different periods. At 1 h before microsurgery, oocytes were placed in cytochalasin B and positioned for micromanipulation. Oocytes undergoing extrusion or already with extruded second polarbodies had 10% of their cytoplasmic volume removed together with the second polarbody. After microsurgery, oocytes were fixed in 10% formalin, stained with 5 μ g Hoechst 33342 and observed under UV epi-fluorescence. Oocytes without any chromatin were considered successfully enucleated. Most oocytes were successfully enucleated when micromanipulated at the times examined (Table 1). Because the efficiency of this enucleation technique is high, checking of oocytes with DNA stain and UV light is not necessary. Significantly lower percentages of enucleation was obtained when blindly removing using the position of the first polarbody to aspirate 30% of the surrounding cytoplasm in oocytes at metaphase (59%) at 24 h from the beginning of *in vitro* maturation.

35

66340-541E109

Table 1

Successful telophase enucleations as performed at different times after exposure to a stimulus to parthenogenetically activate secondary oocytes

	Time after activation			
	3 h	4 h	5 h	Total
Number manipulated	37	38	43	118
Successful enucleation	36	37	40	113
(%)	(97%)	(97%)	(93%)	(96%)

5

Example 2

Nuclear transfer with morula-stage blastomeres

Bovine secondary oocytes were matured *in vitro* and enucleated using the technique described above (telophase enucleation). Morula-stage embryos were disaggregated and individual blastomeres were inserted into the perivitelline space of enucleated oocytes. Fusion between the membranes of blastomeres and oocytes was obtained with an electric pulse that causes fusion between the membranes of the donor and recipient cells. The electrical parameters used were double 60 μ sec pulses of 1.5 KVolts per cm. After fusion the embryos were cultured for 7 days in the presence of Menezo's B2 medium supplemented with 10% fetal calf serum.

20

Table 2

Fusion and development of bovine oocytes reconstructed with nuclei from morula-stage blastomeres recovered 5 days after IVF

	Number	Fused	Blastocyst	No. nuclei
Telophase II	215	129	49	126 \pm 11
(%)		(58%)	(38%)	
Metaphase II	248	151	24	84 \pm 9
(%)		(60%)	(16%)	

25

000210-6947E09

Example 3

Nuclear transfer with non-starved bovine ES cells

Bovine embryo stem (ES)-like cells were obtained from day 8 blastocyst stage embryos produced entirely *in vitro*. ICMs were plated onto mitomycin-inactivated mouse fibroblasts. Established ES-like lines were disaggregated by short exposure to trypsin using a narrow pipette. Isolated cells were placed in the perivitelline space of enucleated oocytes and exposed to an electric pulse that causes fusion between the membranes of the donor and recipient cells. The electrical parameters used were double 100 μ sec pulses of 1.5 KVolts per cm. Electrical stimulation was performed as soon as possible after placing the nuclear donor cell in the perivitelline space to obtain better fusion results. After fusion the embryos are cultured for 7 days in the presence of Menezo's B2 medium supplemented with 10% fetal calf serum.

Table 3

Fusion and development of bovine oocytes reconstructed with nuclei from ES-like cells exposed to 5% of FCS

	Number	Fused	Cleaved	Blastocyst
Telophase II	38	11	5	3
(%)		(30%)	(45%)	(27%)
Metaphase II	33	12	2	1
(%)		(36%)	(17%)	(8%)

Example 4

Nuclear transfer with serum-starved bovine ES cells

Bovine embryo stem (ES)-like cells were cultured in medium with 0.5% FCS for 5 days before micromanipulation. As described above, ES-like cells were disaggregated, placed in the perivitelline space of enucleated oocytes and exposed to an electric pulse to cause fusion between the membranes of the donor and

recipient cells. After fusion the embryos are cultured for 7 days in the presence of Menezes's B2 medium supplemented with 10% fetal calf serum.

5

Table 4

Fusion and development of bovine reconstructed with nuclei from bovine ES-like cells exposed (starved) to low concentrations (0.5%) of FCS

	Number	Fused	Cleaved	Blastocyst
Telophase II (%)	38	13 (34%)	3 (23%)	2 (27%)
Metaphase II (%)	42	13 (31%)	4 (31%)	1 (15%)

10

Example 5

Nuclear transfer with starved and non-starved bovine fetal fibroblasts

Bovine fetal fibroblast cells were recovered from day 50 fetuses and passaged in medium D-MEM with 10% FCS. Non-starved fibroblast cells were recovered during growth at 2 days after passaging. Serum starved cells were exposed to medium with 0.5% serum for 5 days before NT. NT was performed as described above.

20

Table 5

Fusion and development of bovine reconstructed with nuclei from bovine fetal fibroblast cells exposed (starved) or not (non-starved) to low concentrations (0.5%) of FCS

	Serum starved			Non-starved		
	Number	Fused	Blast.	Number	Fused	Blast.
Telophase II (%)	69	52 (75%)	2 (4%)	54	20 (37%)	1 (5%)
Metaphase II (%)	60	39 (65%)	9 (24%)	71	49 (69%)	11 (22%)

25

668240-043009

Example 6

Nuclear transfer with starved and non-starved bovine fetal fibroblasts transfected with a GFP construct

Bovine fetal fibroblast cells were recovered from day 50 fetuses and passaged in medium D-MEM with 10% FCS. The fetal fibroblast cells were transfected with a constructs containing the CMV/eGFP gene (plasmid pGREEN LANTERN-1, Life Technologies). This construct contains the reporter gene Green Fluorescence Protein (GFP) from *Aequorea victoria* jellyfish, which codes for a naturally fluorescent protein requiring no substrate for visualization. The GFP used is "humanized" (i.e., codon sequence) and mutated to contain threonine at position 65 to enhance fluorescence peaking. The advantage of using this fluorescent gene as a reporter being that it yields bright green fluorescence when living or fixed cells are illuminated with blue light and increases our sensitivity of detection. The plasmid contains the CMV immediate early enhancer/promoter upstream of the GFP gene, followed by SV40 t-intron and polyadenylation signal. NT was performed as described above.

Table 6

Fusion and development of bovine reconstructed with nuclei from bovine fetal fibroblast cells transfected with a GFP construct and exposed (S.; starved for 4 days) or not (N.S.; non-starved at day 0 and day 2 after seeding) to low concentrations (0.5%) of FCS

	Cell Treatment	Number	Fused (%)	Blastocysts	No Cells
Telophase II	N.S. day 0	20	13 (65%)	3 (23%)	94
Metaphase II	N.S. day 0	45	38 (84%)	4 (11%)	120
Metaphase II	N.S. day 2	54	40 (74%)	none	n.a.
Metaphase II	S. day 4	48	37 (77%)	3 (8%)	n.a.

While the invention has been described in connection with specific embodiments thereof, it will be

understood that it is capable of further modifications
and this application is intended to cover any varia-
tions, uses, or adaptations of the invention following,
in general, the principles of the invention and
5 including such departures from the present disclosure
as come within known or customary practice within the
art to which the invention pertains and as may be
applied to the essential features hereinbefore set
forth, and as follows in the scope of the appended
10 claims.

668240-647E709

1. A method of preparing an enucleated host oocyte for transferring nuclei from embryonic, germinal or somatic cells, which comprises the steps of:

2. The method of claim 1, wherein said oocyte of step a) has a first polarbody and said artificial means is chemical means.

4. The method of claim 3, wherein step b) is performed after oocytes are cultured for a period of time sufficient to allow for extrusion of a second polarbody.

6. The method of claim 5, wherein step b) is effected by microsurgically removing said second polar with about one tenth of the cytoplasm surrounding said second polarbody.

8. A method of reconstituting an animal embryo, which comprises the steps of:

9. The method of claim 8, wherein said oocyte of step a) has a first polarbody and said artificial means is chemical means.

10. The method of claim 9, wherein said chemical means is ethanol or ionomycin.

11. The method of claim 10, wherein step b) is performed after oocytes are cultured for a period of time sufficient to allow for extrusion of a second polarbody.

12. The method of claim 11, wherein step b) is performed with oocytes in a medium with cytoskeletal inhibitors.

13. The method of claim 12, wherein step b) is effected by microsurgically removing said second polar with about one tenth of the cytoplasm surrounding said second polarbody.

14. The method of claim 13, wherein step c) is effected by introducing a single cell containing a diploid nucleus into said enucleated oocyte by cell fusion or by microinjection.

15. The method of claim 11, wherein said oocyte is a secondary (M-II) oocyte.

668210-6311E109

ABSTRACT OF THE INVENTION

The present invention relates to an improved method for obtaining an enucleated host oocyte for transferring nuclei from embryonic, germinal and somatic cells with the objective of cloning or multiplying mammals, and to a method of reconstituting an animal embryo.

668240-0947E109

1. Bordignon V, Smith LC, 1998, Mol.Reprod.Dev. 49:29-36
2. Campbell KHS, et al., 1996, Nature 380:64-66
3. Cibelli, J. B et al., 1998a, Science 280(5367), 1256-1258. 98a.
4. Cibelli JB et al., 1998b, Nat Biotechnol 16:642-646
5. Collas P et al., 1992, Biol.Reprod. 46:501-511
6. Schnieke AE et al., 1997, Science 278:2130-2133
7. Smith LC, 1993, J.Reprod.Fertil. 99:39-44
8. Stice SL et al., 1994, Mol.Reprod.Dev. 38:61-68
9. Stice SL et al., 1996, Biol.Reprod. 54:100-110
10. Wakayama T et al., 1998, Nature 394:369-372
11. Willadsen S, 1986, Nature 320:63-65
12. Wilmut I et al., 1997, Nature 385:810-813.
13. Wells et al., 1999, Biol. Reprod., 60:996-1005




Fig. 1